ResMed Inc. (RMD) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (59% profit margin, 23% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ResMed Inc. (RMD) advanced +1.06% to $252.83 as options desks priced 56% call premium vs. 44% put protection around the $248 max-pain magnet. High-quality cash engine (59% profit margin, 23% return on capital) with steady institutional support.
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% abo
ResMed (RMD) passes a quality dividend screen with a 7/10 dividend rating, strong profitability, and healthy balance sheet despite a modest 1.25% yield.
ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health
S&P 500 unusual-volume screen for Oct. 30, 2026: Reddit fell 30.15% on heavy volume, Global Payments rose 10.41%, and several other stocks traded above average.
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.
Sleep device revenue grew 6% as AI tools boost therapy compliance and partnerships expand.
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the
Moby summary of ResMed Inc.'s Q1 2027 earnings call
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RMD today. View full Setup Ledger →
Why RMD Stock advanced +1.06% Today — RQD Quant Desk Flash. High-quality cash engine (59% profit margin, 23% return on capital) with steady institutional support.